August 9, 2023 RNAi Therapeutics on the European Pharmaceutical Review Podcast Paul Nioi, PhD, VP of Discovery and Translational Research discussed RNAi therapeutics on the The European Medical Review Podcast. Read More ›
March 16, 2023 Alnylam's Paul Nioi, PhD on The Genetics Podcast: Using Genetics in Drug Target Discovery Paul Nioi, PhD, VP of Discovery and Translational Research and Head of Alnylam Human Genetics recently spoke with Dr. Patrick Short on The Genetics Podcast. Read More ›
September 10, 2020 Brendan Martin on the Pharmaphorum Podcast Alnylam’s Brendan Martin, Head of Europe, Middle East, Africa, and Canada and General Manager for the UK & Ireland, recently spoke on the Pharmaphorum podcast. Read More ›
June 15, 2020 Rethinking R&D to Prime it for Future Success Much of the world has this romantic notion that drug discovery involves a small numbers of hero scientists toiling away in a lab until – Eureka! Read More ›
May 1, 2020 John Maraganore on the "I Am BIO" Podcast: Destroying COVID's Genome Our CEO John Maraganore recently spoke with Biotechnology Innovation Organization (BIO) CEO and Chairman Jim Greenwood on the "I Am BIO" podcast. Read More ›
September 2, 2019 ORION-11: A Landmark Event for RNAi Therapeutics The results from the ORION-11 Phase 3 study of inclisiran, presented earlier today at the European Society of Cardiology meeting represent a landmark event... Read More ›
May 12, 2019 What is RNAi and How Do RNAi Therapeutics Work? What is RNAi? This video explains how Alnylam is leading the translation of RNAi to create an entirely new class of innovative medicines to treat disease. Read More ›
February 20, 2019 Alnylam Named a Fast Company World's Most Innovative Company for 2019 Alnylam has been named #3 in Biotech on Fast Company's World's 50 Most Innovative Company for 2019. Read More ›
January 3, 2019 John Maraganore Talks RNAi on Chemical & Engineering News Podcast John Maraganore talks with Chemical & Engineering News' Lisa Jarvis and Ryan Cross on this episode of C&EN's Stereo Chemistry podcast. Read More ›
May 9, 2018 First Rounders: John Maraganore Our CEO John Maraganore, Ph.D. recently chatted with the Nature Biotechnology Podcast about his path into science, through research and ultimately into biotech. Read More ›

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site